BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
08 juin 2023 07h00 HE | BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Aceragen_Logo_Full_Color.png
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
17 janv. 2023 08h00 HE | Idera Pharmaceuticals, Inc.
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 16h05 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Acquires Aceragen
28 sept. 2022 16h09 HE | Idera Pharmaceuticals, Inc.
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00...